Skip to main content

Baricitinib or Tocilizumab Use in Hospitalized Patients with a COVID-19 Diagnosis: A Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Medical Product
baricitinib
tocilizumab
Health Outcome(s)
emergency use authorization (EUA) utilization
Description

The objective of this request was to identify patients of all ages with evidence of baricitinib or tocilizumab use in the hospital setting, with and without a COVID-19 diagnosis and/or COVID-19 positive lab. We also assessed evidence of concomitant use of remdesivir with baricitinib and systemic corticosteroids with tocilizumab.

The study period includes data from April 1, 2020 to March 31, 2021. We distributed this request to 22 National Patient-Centered Clinical Research Network (PCORnet) DataMarts on September 21, 2021.

Deliverables (1)
Sentinel Modular Program Report: Baricitinib or Tocilizumab Use in Hospitalized Patients with a COVID-19 Diagnosis: A Descriptive Analysis
Additional Details
FDA Center
CDER
Time Period
April 1, 2020 - March 31, 2021
Analysis Type
PCORnet Descriptive Analysis
Population / Cohort
All individuals
Data Sources
National Patient-Centered Clinical Research Network (PCORnet)
Related Links
Sentinel Drug Study: Olumiant (Baricitinib) and Actemra (Tocilizumab) & Emergency Use Authorization (EUA) Utilization